Fresh Tracks Therapeutics, Inc. — Cyborg Score 1/10
Challenged
Clinical-stage biopharmaceuticals
Strategic Profile
The company was formerly known as Brickell Biotech, Inc. and rebranded in September 2022. Prior to dissolution, it aimed to leverage experienced leadership with track records in commercializing first-in-class pharmaceutical products.
Cyborg Score Rationale
The company filed for dissolution in February 2025 after losing Nasdaq listing status in December 2023. No meaningful operations exist as of today's date (June 2026).
Top Insights
Dissolved in February 2025 following Nasdaq delisting
Provided $0.96 per share distribution to shareholders as of February 2025
Previously focused on autoimmune and inflammatory disease therapies
Leadership had extensive experience with first-in-class pharmaceutical launches
Recent Developments
(February 2025) Certificate of Dissolution filed with Delaware Secretary of State
(December 2023) Stock suspended from Nasdaq Capital Market trading
(September 2022) Rebranded from Brickell Biotech to Fresh Tracks Therapeutics
Open the full interactive Fresh Tracks Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.